**SUPPLEMENTARY FILE**

**Supplementary Table 1:** Least-Square mean (SE) change from baseline by visit and Least-Square means difference at the end of 8 weeks (Full Analysis Set).

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | | **Anhedonia** | | | **Amotivation** | | |
| **Placebo**  **(n=383)** | **Venlafaxine XR**  **(n=456)** | **p-valuea** | **Placebo**  **(n=502)** | **Venlafaxine XR**  **(n=585)** | **p-valuea** |
| Observed Mean (SD) | Baseline | 16.90 (3.43) | 16.92 (3.71) | - | 5.85 (1.09) | 5.74 (1.27) | - |
| LS Mean change from baseline (SE) by visit | Week 1 | -2.31 (0.20) | -2.58 (0.19) | 0.3336 | -0.76 (0.06) | -0.82 (0.06) | 0.4872 |
| Week 2 | -3.58 (0.26) | -4.94 (0.24) | 0.0001 | -1.23 (0.08) | -1.57 (0.07) | 0.0013 |
| Week 3 | -4.98 (0.30) | -6.42 (0.29) | 0.0005 | -1.68 (0.08) | -2.06 (0.08) | 0.0017 |
| Week 4 | -5.76 (0.31) | -7.87 (0.29) | <0.0001 | -2.03 (0.09) | -2.52 (0.09) | 0.0001 |
| Week 6 | -7.21 (0.35) | -9.45 (0.32) | <0.0001 | -2.49 (0.10) | -3.12 (0.09) | <0.0001 |
| Week 8 | -7.24 (0.36) | -10.40 (0.33) | <0.0001 | -2.59 (0.11) | -3.46 (0.10) | <0.0001 |
|  | | **Anhedonia** | | | **Amotivation** | | |
| **LS Means**  **(95% CI)** | **LS Means difference**  **(95% CI)** | **p-valueb** | **LS Means**  **(95% CI)** | **LS Means Difference**  **(95% CI)** | **p-valueb** |
| Placebo (n=378, n=496) | | -6.33 (-6.99, -5.68) |  |  | -2.24 (-2.43, -2.06) |  |  |
| Venlafaxine XR (n=438, n=558) | | -9.06 (-9.68, -8.44) | -2.73 (-3.63, -1.82) | <0.0001 | -3.02 (-3.20, -2.84) | -0.78 (-1.04, -0.52) | <0.0001 |

ap-value derived from MMRM (mixed-effects model for repeated measures) model including terms for study, treatment, visit, treatment-by-visit, and baseline score.

bp-value derived from ANCOVA (analysis of covariance) model including terms for study, treatment, and baseline score, and using Last Observation Carried Forward (LOCF)